Literature DB >> 22645137

Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins.

Gregory R Robbins1, Agnieszka D Truax, Beckley K Davis, Lu Zhang, W June Brickey, Jenny P-Y Ting.   

Abstract

Most of the nucleotide-binding domain, leucine-rich repeat (NLR) proteins regulate responses to microbial and damage-associated products. Class II transactivator (CIITA) has a distinct function as the master regulator of class II major histocompatibility complex (MHC-II) transcription. Recently, human NLRC5 was found to regulate MHC-I in cell lines; however, a host of conflicting positive and negative functions has been attributed to this protein. To address the function of NLRC5 in a physiologic setting, we generated an Nlrc5(-/-) strain that contains a deletion in the exon that encodes the nucleotide-binding domain. We have not detected a role for this protein in cytokine induction by pathogen-associated molecular patterns and viruses. However, Nlrc5(-/-) cells showed a dramatic decrease of classical (H-2K) and nonclassical (Tla) MHC-I expression by T/B lymphocytes, natural killer (NK) cells, and myeloid-monocytic lineages. As a comparison, CIITA did not affect mouse MHC-I expression. Nlrc5(-/-) splenocytes and bone marrow-derived macrophages were able to up-regulate MHC-I in response to IFN-γ; however, the absolute levels of MHC-I expression were significantly lower than WT controls. Chromatin immunoprecipitation of IFN-γ-treated cells indicates that Nlrc5 reduced the silencing H3K27me3 histone modification, but did not affect the activating AcH3 modification on a MHC-I promoter. In summary, we conclude that Nlrc5 is important in the regulation of MHC-I expression by reducing H3K27me3 on MHC-I promoter and joins CIITA as an NLR subfamily that controls MHC gene transcription.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22645137      PMCID: PMC3397855          DOI: 10.1074/jbc.M112.364604

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  NLRC5 limits the activation of inflammatory pathways.

Authors:  Szilvia Benko; Joao G Magalhaes; Dana J Philpott; Stephen E Girardin
Journal:  J Immunol       Date:  2010-07-07       Impact factor: 5.422

Review 2.  Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease.

Authors:  M Krawczyk; W Reith
Journal:  Tissue Antigens       Date:  2006-03

3.  Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains.

Authors:  Jonathan A Harton; Michael W Linhoff; Jinghua Zhang; Jenny P-Y Ting
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

4.  NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.

Authors:  Francesco Staehli; Kristina Ludigs; Leonhard X Heinz; Queralt Seguín-Estévez; Isabel Ferrero; Marion Braun; Kate Schroder; Manuele Rebsamen; Aubry Tardivel; Chantal Mattmann; H Robson MacDonald; Pedro Romero; Walter Reith; Greta Guarda; Jürg Tschopp
Journal:  J Immunol       Date:  2012-03-12       Impact factor: 5.422

5.  GTP binding by class II transactivator: role in nuclear import.

Authors:  J A Harton; D E Cressman; K C Chin; C J Der; J P Ting
Journal:  Science       Date:  1999-08-27       Impact factor: 47.728

6.  NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression.

Authors:  Torsten B Meissner; Yuen-Joyce Liu; Kyoung-Hee Lee; Amy Li; Amlan Biswas; Marja C J A van Eggermond; Peter J van den Elsen; Koichi S Kobayashi
Journal:  J Immunol       Date:  2012-04-06       Impact factor: 5.422

7.  Distinct transcriptional pathways regulate basal and activated major histocompatibility complex class I expression.

Authors:  T Kevin Howcroft; Aparna Raval; Jocelyn D Weissman; Anne Gegonne; Dinah S Singer
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

8.  The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses.

Authors:  Sven Kuenzel; Andreas Till; Michael Winkler; Robert Häsler; Simone Lipinski; Sascha Jung; Joachim Grötzinger; Helmut Fickenscher; Stefan Schreiber; Philip Rosenstiel
Journal:  J Immunol       Date:  2010-01-08       Impact factor: 5.422

9.  Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition.

Authors:  Tsuyoshi Tanabe; Mathias Chamaillard; Yasunori Ogura; Li Zhu; Su Qiu; Junya Masumoto; Partho Ghosh; Anthony Moran; Martina M Predergast; Gerard Tromp; Charlene J Williams; Naohiro Inohara; Gabriel Núñez
Journal:  EMBO J       Date:  2004-03-25       Impact factor: 11.598

10.  Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.

Authors:  Agnieszka D Truax; Meghna Thakkar; Susanna F Greer
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more
  36 in total

Review 1.  NLRC5/CITA: A Key Player in Cancer Immune Surveillance.

Authors:  Sayuri Yoshihama; Saptha Vijayan; Tabasum Sidiq; Koichi S Kobayashi
Journal:  Trends Cancer       Date:  2017-01-10

2.  Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.

Authors:  Christopher R Lupfer; Kate L Stokes; Teneema Kuriakose; Thirumala-Devi Kanneganti
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

3.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Authors:  Sayuri Yoshihama; Jason Roszik; Isaac Downs; Torsten B Meissner; Saptha Vijayan; Bjoern Chapuy; Tabasum Sidiq; Margaret A Shipp; Gregory A Lizee; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

Review 4.  Expression regulation and function of NLRC5.

Authors:  Yikun Yao; Youcun Qian
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

Review 5.  NLRC5: new cancer buster?

Authors:  Feng Tang; Yadi Xu; Bing Zhao
Journal:  Mol Biol Rep       Date:  2020-01-10       Impact factor: 2.316

Review 6.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

7.  Canonical Inflammasomes Drive IFN-γ to Prime Caspase-11 in Defense against a Cytosol-Invasive Bacterium.

Authors:  Youssef Aachoui; Yuji Kajiwara; Irina A Leaf; Dat Mao; Jenny P-Y Ting; Jörn Coers; Alan Aderem; Joseph D Buxbaum; Edward A Miao
Journal:  Cell Host Microbe       Date:  2015-08-27       Impact factor: 21.023

8.  T Cell Priming by Activated Nlrc5-Deficient Dendritic Cells Is Unaffected despite Partially Reduced MHC Class I Levels.

Authors:  Giorgia Rota; Kristina Ludigs; Stefanie Siegert; Aubry Tardivel; Leonor Morgado; Walter Reith; Aude De Gassart; Greta Guarda
Journal:  J Immunol       Date:  2016-03-04       Impact factor: 5.422

9.  NLRC5/CITA: a novel regulator of class I major histocompatibility complex genes.

Authors:  Koichi S Kobayashi
Journal:  J immunodefic Disord       Date:  2012

Review 10.  NLRC5: a key regulator of MHC class I-dependent immune responses.

Authors:  Koichi S Kobayashi; Peter J van den Elsen
Journal:  Nat Rev Immunol       Date:  2012-12       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.